Clinical trials: Linezolid
Skin and Subcutaneous Tissue Bacterial Infections
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
This is a randomized, double-blind, double-dummy, multicenter, global Phase 3 study of IV to oral TR-701 FA 200 mg once daily for 6 days versus IV to oral Zyvox® (linezolid) 600 mg every 12 hours for 10 days for the treatment of…
- Trial name
- NCT01421511
- Testing
- TR-701 FA, Linezolid
- Where
- 117 sites in United States, Argentina and 9 more
- Volunteers
- 666 people
- Sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Skin/Soft Tissue Infections, Methicillin Resistant Staphylococcus Aureus (MRSA)
Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
To determine if linezolid is superior to vancomycin in the treatment of complicated skin and soft tissue infections due to MRSA in adult subjects
- Trial name
- NCT00087490
- Testing
- linezolid, vancomycin
- Where
- 126 sites in United States, Argentina and 14 more
- Volunteers
- 1,077 people
- Sponsor
- Pfizer
Pneumonia
Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)
This is a 1:1 ratio, randomized, double-blind, double-dummy, multicenter, global Phase 3 study of tedizolid phosphate (TR-701 FA) 200 mg intravenous (IV) once daily for 7 days versus linezolid (Zyvox®, Zyvoxid®, etc) 600 mg IV…
- Trial name
- NCT02019420
- Testing
- Tedizolid phosphate, Linezolid
- Volunteers
- 726 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Methicillin-Resistant Staphylococcus Aureus (MRSA), Hospital-Acquired Pneumonia
Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin
The objective of this study is to review the local management of patients with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia treated with vancomycin or linezolid with the goal to define if any difference…
- Trial name
- NCT01561469
- Testing
- Linezolid, Vancomycin
- Volunteers
- 188 people
- Sponsor
- Pfizer
Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP)
Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens
The primary objective of this study is to compare all-cause mortality at Day 14 in participants receiving cefiderocol with participants receiving the comparator, meropenem, in adults with hospital-acquired bacterial pneumonia…
- Conditions
- Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP), Ventilator Associated Pneumonia (VAP)
- Trial name
- APEKS-NP (NCT03032380)
- Testing
- Cefiderocol, Meropenem, Linezolid
- Where
- 119 sites in United States, Belgium and 17 more
- Volunteers
- 300 people
- Sponsor
- Shionogi
Staphylococcal Infections
Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)
Drug use investigation of Zyvox for patients with Methicillin-resistant Staphylococcus aureus (MRSA) infection disease. The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from…
- Trial name
- NCT00666276
- Testing
- linezolid (Zyvox)
- Volunteers
- 1,004 people
- Sponsor
- Pfizer
Infectious Skin Diseases, Bacterial Skin Diseases
Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections
The purpose of this study is to assess the efficacy, safety and tolerability of RX-1741, an oxazolidinone, versus linezolid, another oxazolidinone, in the treatment of uncomplicated skin and skin structure infections
- Conditions
- Infectious Skin Diseases, Bacterial Skin Diseases, Staphylococcal Skin Infections, Streptococcal Infections
- Trial name
- NCT00646958
- Testing
- Radezolid, Linezolid
- Where
- 19 sites in United States
- Volunteers
- 150 people
- Sponsor
- Melinta Therapeutics, Inc.
Abscess, Wound Infection
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a…
- Conditions
- Abscess, Wound Infection, Surgical Site Infection, Cellulitis
- Trial name
- NCT01339091
- Testing
- Dalbavancin, Vancomycin / Linezolid
- Where
- 91 sites in United States, Canada and 6 more
- Volunteers
- 573 people
- Sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
Abscess, Wound Infection
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a…
- Conditions
- Abscess, Wound Infection, Surgical Site Infection, Cellulitis
- Trial name
- NCT01431339
- Testing
- IV Dalbavancin, Vancomycin/Linezolid
- Where
- 137 sites in United States, Bulgaria and 12 more
- Volunteers
- 739 people
- Sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
Bacterial Infections
MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection
The purpose of this study is to determine whether MRX-I is as safe and effective as Linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections
- Trial name
- ABSSSI (NCT02269319)
- Testing
- MRX-I, Linezolid
- Volunteers
- 120 people
- Sponsor
- MicuRx
Community Acquired Pneumonia
Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia
This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate to severe community-acquired bacterial pneumonia.
- Trial name
- LEAP (NCT02559310)
- Testing
- lefamulin, Moxifloxacin, Linezolid
- Where
- 99 sites in United States, Argentina and 16 more
- Volunteers
- 551 people
- Sponsor
- Nabriva Therapeutics AG
Bacterial Infections, Skin Structures and Soft Tissue Infections
Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to linezolid in the treatment of adults with acute bacterial skin and skin structure infections.
- Trial name
- NCT02378480
- Testing
- Omadacycline, Linezolid
- Where
- 78 sites in United States, Bulgaria and 12 more
- Volunteers
- 655 people
- Sponsor
- Paratek Pharmaceuticals Inc
Gram-Positive Bacterial Infections
Post Marketing Surveillance Study on Linezolid
The purpose of this study is to determine if Linezolid is safe for adult Filipino patients diagnosed with gram positive infections.
- Trial name
- A5951090 (NCT01564758)
- Testing
- Linezolid
- Volunteers
- 99 people
- Sponsor
- Pfizer
Skin and Subcutaneous Tissue Bacterial Infections
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
The purpose of this study is to compare clinical response to the measurement techniques of several objective measures of clinical efficacy for use in future ABSSSI (Acute Bacterial Skin and Skin Structure Infection) clinical…
- Trial name
- NCT01283581
- Testing
- Delafloxacin, Linezolid, Vancomycin
- Where
- 31 sites in United States
- Volunteers
- 256 people
- Sponsor
- Melinta Therapeutics, Inc.
Bacterial Infections
A Study To Assess The Effect Of Linezolid On QTc Interval
The FDA has asked Pfizer to assess the risk of linezolid on QT interval (obtained from ECG readings) which could predispose patients to ventricular arrhythmias. This study is conducted to satisfy this requirement.
- Trial name
- NCT00795145
- Testing
- Linezolid 900 mg, Linezolid 1200 mg, Linezolid 600 mg
- Where
- Singapore
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Pfizer
Neoplasms, Febrile Neutropenia
Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
This study will evaluate the effect, safety, and tolerability of ceftazidime-avibactam (CAZ-AVI) plus vancomycin or linezolid compared to standard of care plus vancomycin or linezolid as empiric therapy in febrile neutropenic…
- Trial name
- NCT02732327
- Testing
- CAZ-AVI, Vancomycin, Linezolid
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Forest Laboratories
Bacteremia, Gram-Positive Bacterial Infections
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
This study will treat hemodialysis patients who have a central catheter that is thought to be infected with a specific bacteria (Gram positive bacteria).
- Trial name
- NCT00108433
- Testing
- Cefazolin IV, Linezolid IV, Vancomycin (IV)
- Where
- 17 sites in United States, Colombia and 5 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
Methicillin Resistant Staphylococcus Aureus (MRSA)
Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
To determine if linezolid is superior to vancomycin in the treatment of nosocomial (acquired in the hospital) pneumonia due to Methicillin Resistant Staphylococcus Aureus (MRSA) in adult subjects.
- Trial name
- ZEPHYR (NCT00084266)
- Testing
- linezolid (Zyvox), vancomycin
- Where
- 177 sites in United States, Argentina and 20 more
- Volunteers
- 1,225 people
- Sponsor
- Pfizer
Infectious Skin Disease, Bacterial Skin Disease
Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)
A Phase II trial to demonstrate the safety and efficacy of PTK 0796 in the treatment of complicated skin and skin structure infections (cSSSI).
- Trial name
- NCT03716024
- Testing
- PTK 0796, Linezolid
- Where
- 11 sites in United States
- Volunteers
- 234 people
- Sponsor
- Paratek Pharmaceuticals Inc
Bacterial Infections
Study of Debio 1450 for Bacterial Skin Infections
The primary objective of this study is to evaluate the efficacy of 2 different doses of intravenous and oral Debio 1450 compared with intravenous vancomycin and oral linezolid in the treatment of patients with staphylococcal…
- Trial name
- NCT02426918
- Testing
- Debio 1450 IV, Debio 1450 Oral, Linezolid
- Where
- 22 sites in United States
- Volunteers
- 330 people
- Sponsor
- Debiopharm International SA